Patents by Inventor Gurpreet Ahluwalia

Gurpreet Ahluwalia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR
    Publication number: 20230414567
    Abstract: Described herein are methods for treating atopic dermatitis that allows for the effective treatment of the disease with an interruption period if certain adverse events are observed. Additionally, described here are new methods of treating moderate to severe atopic dermatitis.
    Type: Application
    Filed: November 8, 2021
    Publication date: December 28, 2023
    Inventors: Gurpreet AHLUWALIA, Maple M FUNG, Andrew Christopher Wesley SELFRIDGE
  • STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
    Publication number: 20230346749
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Application
    Filed: December 1, 2022
    Publication date: November 2, 2023
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR
    Publication number: 20230338336
    Abstract: Provided are methods of treatment of alopecia areata comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 6, 2021
    Publication date: October 26, 2023
    Inventors: Catherine M Crosby, Gurpreet Ahluwalia, Andrew Christopher Wesley Selfridge
  • Stabilized oxymetazoline formulations and their uses
    Patent number: 11517560
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: December 6, 2022
    Assignee: EPI HEALTH, LLC
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
    Publication number: 20210169855
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Application
    Filed: July 9, 2020
    Publication date: June 10, 2021
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • RETINOID TOPICAL COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS
    Publication number: 20210162049
    Abstract: A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 3, 2021
    Inventors: Michael G. Oefelein, Jeffrey R. Ehrhardt, Gurpreet Ahluwalia
  • Stabilized oxymetazoline formulations and their uses
    Patent number: 10751325
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: August 25, 2020
    Assignee: EPI HEALTH, LLC
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Retinoid Topical Compositions and Methods for Treating Skin Conditions
    Publication number: 20190365899
    Abstract: A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Michael G. Oefelein, Jeffrey R. Ehrhardt, Gurpreet Ahluwalia
  • STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
    Publication number: 20190365713
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Application
    Filed: April 10, 2019
    Publication date: December 5, 2019
    Inventors: Pramod SARPOTDAR, Kevin WARNER, Steven ZHANG, Gurpreet AHLUWALIA, Amy KUANG
  • Retinoid topical compositions and methods for treating skin conditions
    Patent number: 10383942
    Abstract: A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: August 20, 2019
    Assignee: Allergan, Inc.
    Inventors: Michael G. Oefelein, Jeffrey R. Ehrhardt, Gurpreet Ahluwalia
  • Stabilized oxymetazoline formulations and their uses
    Patent number: 10335391
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: July 2, 2019
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
    Publication number: 20180263962
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 20, 2018
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Stabilized oxymetazoline formulations and their uses
    Patent number: 9974773
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 22, 2018
    Assignee: Allergan, Inc.
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Stabilized oxymetazoline formulations and their uses
    Patent number: 9801857
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: October 31, 2017
    Assignee: Allergan, Inc.
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
    Publication number: 20170151217
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS
    Publication number: 20160279143
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Application
    Filed: November 12, 2015
    Publication date: September 29, 2016
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney G. Edwards, Scott M. Whitcup
  • Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
    Patent number: 9226931
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: January 5, 2016
    Assignee: Allergan, Inc.
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney G. Edwards, Scott M. Whitcup
  • Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
    Patent number: 9216183
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: December 22, 2015
    Assignee: Allergan, Inc.
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney Edwards, Scott M. Whitcup
  • STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
    Publication number: 20150359781
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Retinoid Topical Compositions and Methods for Treating Skin Conditions
    Publication number: 20150320732
    Abstract: A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.
    Type: Application
    Filed: July 20, 2015
    Publication date: November 12, 2015
    Inventors: Michael G. Oefelein, Jeffrey R. Ehrhardt, Gurpreet Ahluwalia